The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer

European Urology

Volumn 65, Issue 1, 2014, Pages 3-6

  Pond, Gregory R ^a   Sonpavde, Guru ^b   De Wit, Ronald ^c   Eisenberger, Mario A ^d   Tannock, Ian F ^e   Armstrong, Andrew J ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f DUKE CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Metastatic castration resistant prostate cancer; Metastatic site; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; HEMOGLOBIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT;

ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VISCERAL METASTASIS; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES;

EID: 84888826025     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.09.024     Document Type: Article

References (10)

1. A.J. Armstrong, E.S. Garrett-Mayer, Y.C. Yang, R. de Wit, I.F. Tannock, and M. Eisenberger A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403
2. A.J. Armstrong, I.F. Tannock, R. de Wit, D.J. George, M. Eisenberger, and S. Halabi The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
3. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
4. K.N. Chi, T. Kheoh, and C.J. Ryan A prognostic model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel [abstract 5013] J Clin Oncol 31 Suppl 2013
5. Y. Loriot, K. Fizazi, J.S. De Bono, D. Forer, M. Hirmand, and H.I. Scher Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract 5065] J Clin Oncol 31 Suppl 2013
6. W.K. Kelly, S. Halabi, and M.A. Carducci Liver metastases to predict for short overall survival in metastatic castration-resistant prostate cancer patients [abstract 4655] J Clin Oncol 30 Suppl 2012
7. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
8. R.W. Ross, M.D. Galsky, and H.I. Scher A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study Lancet Oncol 13 2012 1105 1113
9. H. Scher, G. Heller, and A. Molina Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract LBA4517) J Clin Oncol 29 Suppl 2011
10. S. Doctor, C.K. Tsao, J.H. Godbold, M.D. Galsky, and W.K. Oh Evolving patterns of metastatic disease in castration-resistant prostate cancer reported in clinical trials from 1990 to 2011 [abstract 5015] J Clin Oncol 31 Suppl 2013